{
    "clinical_study": {
        "@rank": "115909", 
        "arm_group": {
            "arm_group_label": "PBASE system 2.0", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that the treatment does not cause any clinically\n      significant effects that would put patients at risk."
        }, 
        "brief_title": "PBASE-system Safety and Tolerability Clinical Investigation", 
        "condition": "Non-patient Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide written informed consent prior to participation in the\n             clinical investigation\n\n          -  Judged by the Investigator as suitable for participation in the study without safety\n             concerns based on medical history, physical examination and laboratory results\n\n          -  Age: 18-65 years of age.\n\n          -  Gender: Male or female subjects.\n\n          -  Negative urine drug screen (amphetamine, benzodiazepines, cocaine, marijuana,\n             metamphetamine, morphine) at screening and Visit 2.\n\n          -  Female subjects have to be post-menopausal for more than one year or use a highly\n             efficient method of contraception (i.e. a method with less than 1% failure rate [e.g.\n             sterilisation, hormone implants, hormone injections, some intrauterine devices,\n             abstinence, or vasectomised partner]). Oral contraceptives: combined pill (estrogen /\n             progestin) and medium-dose progestin pill (for example desogestrel 75ug) are accepted\n             only in combination with the partner using condoms.\n\n          -  Willing and able to comply with all study procedures and restrictions\n\n        Exclusion Criteria:\n\n          -  A diagnosis of asthma or chronic obstructive pulmonary disorder.\n\n          -  Ongoing respiratory infection including the nasal cavity.\n\n          -  Current malignancy of any kind.\n\n          -  History of frequent nose bleeds or a condition that increases the risk of excessive\n             bleeding.\n\n          -  Pronounced anterior septal deviation or other significant nasal pathology.\n\n          -  Known allergy to polyvinylchloride or medicinal liquid paraffin.\n\n          -  Ongoing treatment with drugs indicated for respiratory or cardiac disorders.\n\n          -  Any disease, condition (medical or surgical) including allergic, immunological and\n             gastro-intestinal conditions and/or chronic medications which, in the opinion of the\n             investigator, might compromise the study results, or would place the subject at\n             increased risk.\n\n          -  Vital signs with clinically significant deviations that would make the subject\n             unsuitable for the study, as judged by the investigator.\n\n          -  Evidence of significant cardiovascular disease defined by the following:\n\n               1. New York Heart Association (NYHA) Class III or IV heart failure;\n\n               2. Presence of symptomatic coronary artery disease or unstable angina;\n\n               3. Persistent arrhythmia requiring chronic pharmacotherapy or implantable device;\n\n               4. Clinically significant abnormalities seen on the screening electrocardiogram as\n                  assessed by the investigator;\n\n          -  Clinically significant deviations in, hematology (including coagulation parameters\n             aPTT and INR) variables, blood chemistry variables or urinalysis as assessed by the\n             investigator.\n\n          -  Positive screening test for HIV or hepatitis B or C\n\n          -  Positive alcohol breath test at Visit 1 or at Visit 2.\n\n          -  Non-smoker since at least six months at time of  screening.\n\n          -  Is currently implanted with an electrical and/or neurostimulator device, including\n             but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep\n             brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.\n\n          -  Previously treated with radiation on the face\n\n          -  Previous radiation therapy to the head or neck regions\n\n          -  Previously treated with an implantable stimulator or any implantable device in the\n             head and / or neck\n\n          -  Has a recent or repeated history of syncope.\n\n          -  Has a recent or repeated history of seizures.\n\n          -  Surgery within the past three months, determined by the PI to be clinically relevant.\n\n          -  Strenuous exercise within 2 days of Visit 1 or Visit 2.\n\n          -  Women who are pregnant or nursing.\n\n          -  Female subjects: unwilling to use adequate contraceptive measures from the signing of\n             the informed consent until end of the study at the follow-up visit.\n\n          -  Received study drug in a clinical trial for an investigational drug within the\n             previous 30 days, or 5 half-lives, whichever is longer.\n\n          -  Blood donation or loss of whole blood exceeding 100 mL within 30 days from screening\n             or plasma within 14 days from screening.\n\n          -  Excessive intake of alcohol, defined as an average daily intake of greater than three\n             units, or a maximum weekly intake of greater than 21 units ((three units equal 250 ml\n             of 12% alcohol by unit wine).\n\n          -  Concurrent condition or risk of non-compliance that, in the investigator's opinion,\n             may affect the interpretation of performance or safety data or which otherwise\n             contraindicates participation in a clinical investigation."
            }, 
            "gender": "Both", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798368", 
            "org_study_id": "PS002"
        }, 
        "intervention": {
            "arm_group_label": "PBASE system 2.0", 
            "intervention_name": "PBASE system 2.0", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 1, 2013", 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study to Evaluate the Safety and Tolerability of Nasal Stimulation Using the PBASE System in Non-patient Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "ECG variables as documented on continuous recording include heart rate, heart rate variability,T-wave morphology, and occurrence of arrhythmias", 
                "measure": "Change in ECG variables", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 1 hour prior to treatment initiation to 3 hours post treatment termination"
            }, 
            {
                "description": "Vital signs measurements include blood pressure, pulse and respiratory rate", 
                "measure": "Change in Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 1 hour prior to treatment initiation, right before treatment initiation, 10 min after treatment termination and 3 hours after treatment termination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chordate Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chordate Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}